CD22 and Burkitt lymphoma: Notably, a dual-targeting strategy combining 177Lu-based CD22-specific radioimmunoconjugates with rituximab has demonstrated high treatment efficacy in Burkitt’s lymphoma xenograft models, suggesting a synergistic effect between anti-CD22 and anti-CD20 therapies [65].